Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hussam A. Noor"'
Autor:
Didier Blanchard, Franck Paganelli, Didier Champagnac, Hervé Le Breton, Patrick Dupouy, Raphael Dauphin, Philippe Castellant, Nicolas Delarche, Anne Lyuycx-Bore, Luc Maillard, Róbert Gábor Kiss, Philippe Druelles, Antoine Gommeaux, Jarosław Wójcik, Marie Claude Morice, Michel Schneeberger, Erwan Bressolette, Alain Kermarrec, Joel Sainsous, Paul Barragan, Romain Didier, Olivier Darremont, Hakim Ben Amer, Gilles Levy, Alain Furber, Thomas Hovasse, Martine Gilard, Bernard Jouve, Jacques Berlan, Irme Ungi, Patrick Ohlmann, Jean Armengaud, Talib Majwal, Pierre Cazaux, Arif A.L. Noryani, Claude Cassat, O. Ormezzano, Didier Carrié, Hussam A. Noor
Publikováno v:
JACC: Cardiovascular Interventions
JACC: Cardiovascular Interventions, Elsevier/American College of Cardiology, 2017, 10 (12), pp.1202-1210. ⟨10.1016/j.jcin.2017.03.049⟩
JACC: Cardiovascular Interventions, Elsevier/American College of Cardiology, 2017, 10 (12), pp.1202-1210. ⟨10.1016/j.jcin.2017.03.049⟩
Objectives The aim of this study was to test the hypothesis that 6-month dual antiplatelet therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients. Background The ITALIC (Is There a Life for DES After Discontinuation of Clopidogr
Autor:
Hervé Le Breton, Didier Carrié, Bernard Jouve, Didier Champagnac, Antoine Gommeaux, Pierre Cazaux, Raphael Dauphin, Erwan Bressolette, Patrick Dupouy, Philippe Druelles, Philippe Castellant, Anne Lyuycx-Bore, Paul Barragan, Jean Armengaud, Franck Paganelli, Michel Schneeberger, Hakim Benamer, Joel Sainsous, Arif A.L. Noryani, Alain Kermarrec, Didier Blanchard, Jacques Berland, Thomas Hovasse, O. Ormezzano, Knut Endresen, Martine Gilard, Claude Cassat, Imre Ungi, Marie-Claude Morice, Gilles Levy, Alain Furber, Jacques Boschat, Patrick Ohlmann, Luc Maillard, Róbert Gábor Kiss, Talib Majwal, Hussam A. Noor, Nicolas Delarche, Oliver Darremont, Jarosław Wójcik
Publikováno v:
Journal of the American College of Cardiology. 65:777-786
Background The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 months to reduce the risk of late stent thrombosis, particularly in those with acute coronary syndrome (ACS). Objectives Th
Autor:
Romain, Didier, Marie Claude, Morice, Paul, Barragan, Arif A L, Noryani, Hussam A, Noor, Talib, Majwal, Thomas, Hovasse, Philippe, Castellant, Michel, Schneeberger, Luc, Maillard, Erwan, Bressolette, Jaroslaw, Wojcik, Nicolas, Delarche, Didier, Blanchard, Bernard, Jouve, Olivier, Ormezzano, Franck, Paganelli, Gilles, Levy, Joël, Sainsous, Didier, Carrie, Alain, Furber, Jacques, Berlan, Olivier, Darremont, Hervé, Le Breton, Anne, Lyuycx-Bore, Antoine, Gommeaux, Claude, Cassat, Alain, Kermarrec, Pierre, Cazaux, Philippe, Druelles, Raphael, Dauphin, Jean, Armengaud, Patrick, Dupouy, Didier, Champagnac, Patrick, Ohlmann, Hakim, Ben Amer, Robert G, Kiss, Irme, Ungi, Martine, Gilard
Publikováno v:
JACC. Cardiovascular interventions. 10(12)
The aim of this study was to test the hypothesis that 6-month dual antiplatelet therapy (DAPT) is noninferior to 24-month DAPT in aspirin-sensitive patients.The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that r
Publikováno v:
Chest. 116:909-913
Purpose The purpose of this investigation is to determine the incidence of acute pulmonary embolism (PE) according to age, sex, and race in a tertiary care general hospital. Background Population-based investigations and autopsy studies have shown th